Financial Performance Forecast - The estimated net profit attributable to shareholders for 2024 is projected to be between CNY 335 million and CNY 576 million, representing a year-on-year decrease of 68% to 45%[2]. - The estimated net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be between CNY 231 million and CNY 472 million, reflecting a year-on-year decrease of 62% to 23%[2]. - The net profit for the same period last year was CNY 1,048.04 million, and the net profit excluding non-recurring gains and losses was CNY 613.73 million[4]. - The earnings per share for the previous year was CNY 0.7006[5]. Factors Affecting Profit - The significant decline in profit is primarily due to the expansion of centralized procurement, intensified market competition, and tightening international demand, along with a previous large non-recurring gain from land disposal[6]. - The company plans to recognize impairment losses, which will also impact the current performance[6]. Uncertainties and Auditing - The performance forecast has not yet been audited by registered accountants, and the impairment testing is still ongoing, which may introduce uncertainties[7]. - The preliminary forecast data is subject to change and the final audited financial data will be disclosed in the 2024 annual report[8].
中国医药(600056) - 2024 Q4 - 年度业绩预告